A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Public ClinicalTrials.gov record NCT00143364. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
Study identification
- NCT ID
- NCT00143364
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,005 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Mar 2005 (Actual)
- Last update posted
- Jun 4, 2007
2003 – 2005
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Palo Alto | California | — | — |
| Pfizer Investigational Site | San Diego | California | — | — |
| Pfizer Investigational Site | Denver | Colorado | — | — |
| Pfizer Investigational Site | Pembroke Pines | Florida | — | — |
| Pfizer Investigational Site | Indianapolis | Indiana | — | — |
| Pfizer Investigational Site | Portland | Maine | — | — |
| Pfizer Investigational Site | Boston | Massachusetts | — | — |
| Pfizer Investigational Site | Albert Lea | Minnesota | — | — |
| Pfizer Investigational Site | Rochester | Minnesota | — | — |
| Pfizer Investigational Site | New York | New York | — | — |
| Pfizer Investigational Site | Rochester | New York | — | — |
| Pfizer Investigational Site | Providence | Rhode Island | — | — |
| Pfizer Investigational Site | Nashville | Tennessee | — | — |
| Pfizer Investigational Site | Madison | Wisconsin | — | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00143364, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2007 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00143364 live on ClinicalTrials.gov.